Ono and Domain in three-way drug discovery deal
Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has signed a collaboration agreement with France’s Domain Therapeutics and Université de Montréal (UdM) to discover novel small molecules targeting G-protein coupled receptors (GPCRs) in the metabolic disease area.
Under the agreement, Ono will collaborate with these partners, using the bioSens-All technology GPCR drug discovery platform that has been in-licensed by Domain from UdM, and their expertise in GPCR medicinal chemistry and pharmacology, to design and optimize innovative small molecules against a GPCR selected as therapeutic target, for a future drug development program.
Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration, and will pay to Domain and UdM an undisclosed upfront sum, funding the collaborative research programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze